Relevant bibliographies by topics / Ensifentrine

Contents

  1. Journal articles
  2. Conference papers

Academic literature on the topic 'Ensifentrine'

Author: Grafiati
Published: 7 June 2025
Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ensifentrine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ensifentrine"

1

Cazzola, Mario, Clive Page, and Maria Gabriella Matera. "Ensifentrine: A First-in-class Bifunctional Drug for the Treatment of Chronic Obstructive Pulmonary Disease." US Respiratory & Pulmonary Diseases 7, no. 2 (2022): 48. http://dx.doi.org/10.17925/usrpd.2022.7.2.48.

Full text
Abstract:
Ensifentrine is an inhaled ‘bifunctional’ dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities. Preclinical research has shown that ensifentrine can induce significant relaxation of human bronchi in vitro and suggested the possibility of a synergistic interaction between ensifentrine and β2-adrenoceptor agonists and, mainly, muscarinic receptor antagonists. Ensifentrine is the only dual phosphodiesterase 3/4 inhibitor under clinical development for the treatment of chronic obstructive pulmonary disease (COPD). It has been shown to induce bronc
APA, Harvard, Vancouver, ISO, and other styles
2

Al Matni, Mohammed Yaman, Lucille Meliton, Steven M. Dudek, and Eleftheria Letsiou. "Dual Inhibition of Phosphodiesterase 3 and 4 Enzymes by Ensifentrine Protects against MRSA-Induced Lung Endothelial and Epithelial Dysfunction." Cells 13, no. 21 (2024): 1750. http://dx.doi.org/10.3390/cells13211750.

Full text
Abstract:
Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition with a high mortality rate for which there are no effective therapeutics. The failure of the alveolar–capillary barrier, composed of lung endothelial (EC) and alveolar epithelial (AEC) cells, is a critical factor leading to excessive inflammation and edema characteristic of acute lung injury (ALI) pathophysiology. Phosphodiesterases (PDE) are enzymes well-recognized for their roles in regulating endothelial permeability and inflammation. Although PDE inhibitors are used as therapeutics for inflammatory diseases like COPD (ch
APA, Harvard, Vancouver, ISO, and other styles
3

Suri, Rajat, and Sanjay Ramakrishnan. "Ensifentrine for COPD." CHEST 167, no. 2 (2025): 305–6. https://doi.org/10.1016/j.chest.2024.08.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rheault, Tara, and Margot MacDonald-Berko. "ANTIINFLAMMATORY PHARMACOLOGY OF ENSIFENTRINE." Chest 158, no. 4 (2020): A2284. http://dx.doi.org/10.1016/j.chest.2020.08.1936.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wakil, Aamrah, Taha Ahmad Siddiqui, and Eesha Arshad. "Novel advances in chronic obstructive pulmonary disease treatment: ensifentrine." Journal of the Pakistan Medical Association 75, no. 03 (2025): 523. https://doi.org/10.47391/jpma.21488.

Full text
Abstract:
Chronic obstructive pulmonary disease (COPD) is a respiratory disorder involving chronic inflammation of the airways and excessive mucous production causing progressive, partially reversible airflow obstruction, and airway remodelling. [1] While a multitude of approved drugs- including short/long-acting muscarinic antagonists (SAMAs/LAMAs), short/long-acting B2-agonists (SABAs/LABAs) and inhaled corticosteroids (ICS)- and combination therapies exist; most patients remain significantly symptomatic on maximal doses and recurrent exacerbations pose a serious burden on their mental health and qual
APA, Harvard, Vancouver, ISO, and other styles
6

Marino, Adriane B., Jenna D. Theroux, Evan S. Drake, James Layton Anderson, and Destiny S. Self. "The Drug Update." Nurse Practitioner 50, no. 2 (2025): 27–40. https://doi.org/10.1097/01.npr.0000000000000271.

Full text
Abstract:
ABSTRACT In the first half of 2024, the US FDA approved several new drugs that have relevance for those practicing in primary care. This article, the winter 2025 edition of the journal's biannual Drug Update, highlights the following new medications: sotatercept-csrk (Winrevair), aprocitentan (Tryvio), resmetirom (Rezdiffra), berdazimer (Zelsuvmi), ceftobiprole medocaril sodium (Zevtera), sofpironium (Sofdra), and ensifentrine (Ohtuvayre).
APA, Harvard, Vancouver, ISO, and other styles
7

Donohue, James F., Tara Rheault, Margot MacDonald-Berko, Thomas Bengtsson, and Kathleen Rickard. "Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD." International Journal of Chronic Obstructive Pulmonary Disease Volume 18 (July 2023): 1611–22. http://dx.doi.org/10.2147/copd.s413436.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cazzola, Mario, Luigino Calzetta, Paola Rogliani, and Maria Gabriella Matera. "Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD." Expert Opinion on Investigational Drugs 28, no. 10 (2019): 827–33. http://dx.doi.org/10.1080/13543784.2019.1661990.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Calzetta, L., M. Gabriella Matera, P. Rogliani, and M. Cazzola. "Ensifentrine. Dual phosphodiesterase PDE3/4 inhibitor, Treatment of COPD, Treatment of cystic fibrosis." Drugs of the Future 44, no. 11 (2019): 845. http://dx.doi.org/10.1358/dof.2019.44.11.3068792.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

BON, JESSICA M., TARA RHEAULT, KATHLEEN A. RICKARD, AMY DIXON, DANIEL REYNER, and BROOKS T. KUHN. "ENSIFENTRINE IMPROVED LUNG FUNCTION, SYMPTOMS, AND QUALITY OF LIFE REGARDLESS OF COPD SEVERITY." CHEST 166, no. 4 (2024): A4958—A4959. http://dx.doi.org/10.1016/j.chest.2024.06.2942.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Conference papers on the topic "Ensifentrine"

1

van den Heuvel, Robert. "Practice-changing results for ensifentrine in COPD." In ATS 2023 International Conference, edited by Rachel Giles. Medicom Medical Publishers, 2023. http://dx.doi.org/10.55788/b490d047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barjaktarevic, I., T. Rheault, T. Bengtsson, and K. Rickard. "Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Calzetta, Luigino, Shima Gholamalishahi, Josuel Ora, and Paola Rogliani. "Impact of ensifentrine on trough FEV1 in COPD: a meta-analysis." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa2996.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

van den Heuvel, Robert. "Ensifentrine delays transition from GOLD B to GOLD E in COPD." In ATS 2024 International Conference, edited by Rachel Giles. Medicom Medical Publishers, 2024. http://dx.doi.org/10.55788/efe86119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rheault, Tara, Martin Kankam, John Ayrton, Thomas Bengtsson, and Kathleen Rickard. "The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa2137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sciurba, F. C., K. Rickard, T. Bengtsson, and T. Rheault. "Ensifentrine Reduces Exacerbation Frequency and Delays Progression From Gold B to Gold E." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2997.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sciurba, F. C., R. A. A. Wise, T. Rheault, T. Bengtsson, and K. Rickard. "Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lea, Simon, Jian Li, Kieran Littolff, Kajaluckcika Vijayacumaran, and Dave Singh. "Anti-inflammatory effects of PDE3/4 inhibitor ensifentrine in peripheral blood mononuclear cells from COPD patients." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.oa2775.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rheault, Tara, Thomas Bengtsson, and Kathleen Rickard. "Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.4786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mathioudakis, Alexander, William Stringer, Tara Rheault, et al. "Ensifentrine treatment improves COPD symptoms and quality of life in a pooled analysis of the ENHANCE trials." In ERS Congress 2024 abstracts. European Respiratory Society, 2024. http://dx.doi.org/10.1183/13993003.congress-2024.pa2991.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ensifentrine' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography